PHC (6523) investor relations material

Executive summary

• Revenue increased 8.1% year-over-year in Q1 FY26 to JPY 90,672 million, with strong sales in Diabetes Management, favorable FX, and price adjustments across all regions.

• Operating profit surged 171% year-over-year to JPY 10,413 million, reflecting margin improvements, cost reductions, and strong segment performance.

• Profit attributable to owners of parent was JPY 6,338 million, reversing a prior-year loss.

• Adjusted EBITDA increased 58.1% year-over-year to JPY 17,253 million, supported by operational gains and one-time items.

• Both revenue and profit exceeded internal forecasts for Q1, but full-year guidance remains unchanged pending further review.

Financial highlights

• Q1 FY26 revenue: JPY 90.7 billion (+8.1% YoY); operating profit: JPY 10.4 billion (+171% YoY); profit attributable to owners: JPY 6.3 billion (+JPY 8.7 billion YoY).

• Adjusted EBITDA for Q1 FY26: JPY 17.3 billion (+58.1% YoY); margin approximately 19.0%.

• Basic earnings per share improved to JPY 50.06 from a loss of JPY 18.55 in the prior year.

• Total assets as of June 30, 2026, were JPY 543,077 million, with equity attributable to owners of parent at JPY 169,314 million.

• Cash and cash equivalents at period end were JPY 41,282 million, up JPY 1,462 million from March 31, 2026.

Outlook and guidance

• Full-year revenue forecast for the year ending March 31, 2027, is JPY 359,700 million, with operating profit expected at JPY 27,000 million (up 19.0% year-over-year).

• Management expects to maintain strong momentum and may consider upward revisions if current trends persist, but no changes to previously announced forecasts.

• Annual dividend forecast remains at JPY 42.00 per share.